Behind the video
You've been WARNED.
Overall Thesis
Kevin views the technology selloff as a leverage and positioning shakeout within an otherwise resilient economy, and endorses the broad bullish interpretation of improving earnings and market breadth. He sees potential relief from Iran negotiations, while acknowledging renewed conflict and excessive leverage as risks.
Narratives
GOOGLAlphabetKevin singles out Google's search weakness as a company-specific reason for its shares to decline. He separates that weakness from the broader economy and AI investment cycle.
Key Arguments
- Search weakness warrants a negative stock view.
- Company-specific earnings problems do not establish an economy-wide downturn.
Risks acknowledged
- His broader market outlook remains strongly bullish.
Predictions (1)
RSPInvesco S&P 500 Equal Weight ETFKevin highlights RSP's proximity to all-time highs as evidence that market breadth and the broader economy remain healthy. This is supporting evidence for his market optimism, without a separate forecast or investment recommendation for RSP.
Key Arguments
- Equal-weight performance remains strong despite the technology selloff.
- Resilient breadth suggests the weakness is concentrated in momentum and leveraged AI positions.
Risks acknowledged
- Technology and momentum positions have experienced substantial declines.
- Forced liquidations can produce further volatility.
INTCIntelKevin argues that Intel's earnings miss and weak consumer PC sales do not establish that the AI boom is ending. He links consumer weakness to high memory prices rather than offering a directional forecast for Intel shares.
Key Arguments
- High memory prices can hurt consumer PC demand.
- Intel's headline earnings weakness should not be generalized into an end to the AI boom.
Risks acknowledged
- Intel missed expectations and its shares fell.
Kevin endorses an ongoing Eli Lilly buying stance and expresses continued enthusiasm for the holding. He says healthcare's rally has helped offset weakness in hardware investments, illustrating the value of portfolio balance.
Key Arguments
- He describes buying Eli Lilly over the preceding several months and remains a fan.
- Healthcare gains have helped offset hardware losses.
- Pharmaceutical forward valuations have caught up to S&P 500 levels.
Risks acknowledged
- The sector has already rallied and its valuation discount has narrowed.
- He is uncertain about the exact duration of his buying.
Predictions (1)
Hedges & Caveats
- Reports of a change in the US negotiating tone could be branding or fake news.
- Iran remains a swing factor, with renewed strikes threatening the optimistic market outlook.
- Leveraged investors may face forced selling even when the underlying investment thesis remains intact.
- Economic resilience does not mean every individual is doing well; AI disruption could weaken workers' pricing power.
- The extreme oil-price scenario is attributed to TS Lombard rather than presented as Kevin's own benchmark-specific forecast.